Nuvectis Pharma Announces FDA Clearance of IND for NXP800
21 juin 2022 08h15 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
13 juin 2022 08h30 HE
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
20 mai 2022 10h21 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR “New Drugs on the Horizon” Session NXP900 Preclinical...
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
13 avr. 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
11 avr. 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
22 mars 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated Phase 1a Clinical Trial for NXP800 Announced Promising Data for NXP900 in Triple Negative...
Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
10 mars 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for...
Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
09 mars 2022 10h12 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
22 févr. 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Data Published in Cancer Research, a journal of the American Association for Cancer Research Publication highlights potent activity of NXP900, a differentiated inhibitor of the SRC/YES1 Kinases ...